TRPM2 and non-small cell lung carcinoma: Thus, TRPM2 elevation occurs not only in EGFRm NSCLC cell lines with acquired resistance to osimertinib, but also in the majority of EGFRm NSCLC tissues relapsed from EGFR‐TKI treatment.